Ignite Creation Date:
2025-12-24 @ 9:34 PM
Ignite Modification Date:
2025-12-25 @ 7:18 PM
Study NCT ID:
NCT04445532
Status:
UNKNOWN
Last Update Posted:
2023-07-07
First Post:
2020-06-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Hepatobiliary Tumors Tissue Samples Acquisition
Sponsor:
Peking Union Medical College Hospital
Organization:
Study Overview
Official Title:
Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors
Status:
UNKNOWN
Status Verified Date:
2023-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets.
Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.
Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.
Detailed Description:
OBJECTIVES:
1. Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS);
2. Observe the evolution of tumors and discover specific diagnostic markers as a control group.
3. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors;
4. To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets
1. Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS);
2. Observe the evolution of tumors and discover specific diagnostic markers as a control group.
3. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors;
4. To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: